Vascular protease‐activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long‐term dabigatran administration – results from a diabetes animal model. (6th February 2019)

• Record Type: Journal Article
• Authors: Scridon, Alina; Mărginean, Alina; Huțanu, Adina; Chinezu, Laura; Gheban, Dan; Perian, Marcel; Vântu, Adriana; Gherțescu, Doina; Fișcă, Paul C.; Șerban, Rǎzvan C.; Chevalier, Philippe; Dobreanu, Dan
• Is Part Of: Journal of thrombosis and haemostasis. Volume 17:Number 3(2019)
• Page Start: 538
• Page End: 550
• Publication Date: 2019-02-06
• Subjects: atherosclerosis -- dabigatran -- platelet aggregation -- thrombin -- thrombin inhibition; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.14386
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract : Essentials The impact of long‐term thrombin inhibition outside the coagulation cascade is far from clear. We aimed to assess the impact of dabigatran etexilate (DE) in diabetic and control rats. In diabetic rats, DE increased platelet aggregation and lead to coronary lipid deposits. Long‐term thrombin inhibition may increase atherosclerotic and atherothrombotic risk. Summary: Background: Besides its role in the coagulation cascade, thrombin contributes to platelet aggregation and to a plethora of non‐hemostatic functions. Objectives: To assess the impact of long‐term thrombin inhibition with dabigatran etexilate (DE) on platelet aggregation and on extrahemostatic thrombin‐related functions in diabetic and control rats. Methods: Markers of inflammation, endothelial dysfunction, oxidative stress, angiogenesis and cell adhesion molecules were quantified in control rats (Control; n = 6), DE‐treated control rats (Control‐Dabi; n = 8), diabetic rats (Diabetes; n = 5), and DE‐treated diabetic rats (Diabetes‐Dabi; n = 8). Agonist‐induced platelet aggregation, aortic and coronary lipid deposits and aortic protease‐activated receptor 4 (PAR4) expression were also assessed. Results: Control‐Dabi rats showed significantly higher high‐sensitivity C‐reactive protein, von Willebrand factor (VWF), vascular endothelial growth factor (VEGF) and fibronectin levels, and significantly lower PAR4 agonist‐induced aggregation, than Control rats. Control‐Dabi rats also showed mild aortic lipid deposits, whereas no such changes were observed in Control rats. Diabetes‐Dabi rats showed significantly higher VWF, VEGF and fibronectin levels than Diabetes rats, and similar PAR4 agonist‐induced aggregation as Diabetes rats, and significantly higher ADP‐induced aggregation than Diabetes rats. Coronary lipid deposits were observed in 75% of Diabetes‐Dabi rats and in none of the Diabetes rats. PAR4 expression was 20.4% higher in Control‐Dabi rats and 27.4% higher in Diabetes‐Dabi rats than in their non‐treated peers. Conclusions: This study indicates that long‐term thrombin inhibition increases vascular PAR4 expression, promotes atherosclerosis‐related mechanisms, and, in diabetic rats, increases platelet aggregation and favors the occurrence of coronary lipid deposits. These experimental data suggest that long‐term thrombin inhibition may increase atherosclerotic and atherothrombotic risk, particularly in the presence of diabetes.